Boston, MA, June 1, 2022 — Corium, Inc., a commercial-stage biopharmaceutical company leading the development and commercialization of novel central nervous system (CNS) therapies, announced that serdexmethylphenidate (SDX), the novel prodrug of dexmethylphenidate (d‑MPH), has significantly lower potential for abuse and fewer stimulant-like adverse events compared to d‑MPH. This peer-reviewed finding appears in the May 2022 publication of Current Medical Research & Opinion. AZSTARYS (serdexmethylphenidate and dexmethylphenidate) is the first and only medicine containing SDX and was approved by the U.S. FDA in March 2021 as a once-daily treatment for ADHD symptoms in patients aged 6 years and older.
Boston, MA, March 28, 2022 — Corium, Inc., a commercial-stage biopharmaceutical company leading the development and commercialization of novel central nervous system (CNS) therapies, announced that its poster, “Serdexmethylphenidate/d-Methylphenidate Capsules for Children With ADHD: Effects on SKAMP‑C Evaluated Over 13 Hours in a Randomized, Double-blind, Placebo-controlled Laboratory Classroom Study,” will be presented at the Academy of Managed Care Pharmacy (AMCP) on March 30, 2022, in Chicago, IL. Corium’s once‑daily oral capsule AZSTARYS (serdexmethylphenidate (SDX) and dexmethylphenidate (d‑MPH)), significantly improved both attention and behavior with a 30‑minute onset and up to 13 hours of duration in children ages 6 to 12 years diagnosed with attention deficit hyperactivity disorder (ADHD), compared to a placebo. An author will report the findings (poster # F21), from a post hoc analysis of a pivotal Phase 3 study, at the AMCP.
Boston, MA, March 14, 2022 — Corium, Inc., a commercial-stage biopharmaceutical company leading the development and commercialization of novel central nervous system (CNS) therapies, announced today the U.S. Food and Drug Administration (FDA) has approved Corium’s ADLARITY (donepezil transdermal system) as a treatment for patients with mild, moderate, or severe dementia of the Alzheimer’s type. ADLARITY is the first and only once-weekly patch to continuously deliver consistent doses of donepezil through the skin, resulting in a low likelihood of adverse gastrointestinal (GI) side effects associated with oral donepezil. ADLARITY is the first approved prescription drug product using Corium’s proprietary CORPLEX transdermal technology, which has been used for years in consumer products.
Boston, MA, January 12, 2022 – PeaceLove Foundation, a nonprofit focused on innovative programs that improve emotional wellbeing by leveraging creativity as a self-care tool, and Corium, Inc., a commercial-stage biopharmaceutical company leading the development and commercialization of novel central nervous system (CNS) therapies, announced an expansion of their existing partnership. Under the new Corium sponsorship, PeaceLove will deliver expressive arts-based Scribl workshops to members of the greater Boston and Grand Rapids, MI communities, where Corium has a presence, and they will also train additional individuals to deliver Scribl workshops at the community level. PeaceLove and Corium have prior existing partnerships, including one that provides Scribl workshops to support the emotional wellbeing of Corium employees.
Boston, MA, October 29, 2021 - Corium, Inc., a commercial-stage biopharmaceutical company leading the development and commercialization of novel central nervous system (CNS) therapies, announced publication of results from its Phase 3 pivotal efficacy study in the November 2021 Journal of Child and Adolescent Psychopharmacology. The study showed that Corium's first-in-class, once-daily oral capsule AZSTARYS (serdexmethylphenidate [SDX] and dexmethylphenidate [d-MPH]) significantly improved attention deficit hyperactivity disorder (ADHD) symptoms compared to placebo in children ages 6 to 12 years with a 30-minute onset, 13-hour duration of efficacy, and well-tolerated safety profile comparable to that observed with other stimulant medications. Data from this study will be presented at CHADD's Virtual International Conference on ADHD.
Boston, MA, October 14, 2021 - Corium, Inc., a commercial-stage biopharmaceutical company leading the development and commercialization of novel central nervous system (CNS) therapies, announced today its first-in-class once-daily oral capsule AZSTARYS (serdexmethylphenidate [SDX] and dexmethylphenidate [d-MPH]), which was approved by the U.S. Food and Drug Administration (FDA) in March 2021, significantly reduced attention deficit hyperactivity disorder (ADHD) symptoms in children ages 6 to 12 years during a phase 3 controlled classroom clinical trial. The results are being presented in a poster and a Meet the Presenter session on October 15, 2021, during the American Psychiatric Nurses Association (APNA) 35th Annual Conference, held virtually on October 13-16. AZSTARYS is the first and only medicine to add the innovative SDX prodrug with d-MPH.
Boston, MA, October 12, 2021 - Corium, Inc., a commercial-stage biopharmaceutical company leading the development and commercialization of novel central nervous system (CNS) therapies, announced today the U.S. Food and Drug Administration (FDA) set a Prescription Drug User Fee (PDUFA) target action date of March 11, 2022 for Corium's new drug application (NDA) for once-weekly ADLARITY (donepezil transdermal system), its lead investigational product and a patch formulation of donepezil for the treatment of patients with dementia due to mild, moderate, or severe Alzheimer's disease. If approved, ADLARITY would be Corium's second CNS product approved for the U.S. market in 12 months.
Corium Secures $235 Million in Debt Financing
Boston, September 27, 2021 (PR NEWSWIRE) - Corium, Inc., a commercial-stage biopharmaceutical company leading the development and commercialization of novel central nervous system (CNS) therapies, today announces that it has closed on a $235 million term loan agreement with Hercules Capital, Inc. (NYSE: HTGC), a leader in specialty financing for life science and technology companies.
Boston, July 21, 2021 (PR NEWSWIRE) - Corium, Inc., a commercial-stage biopharmaceutical company leading the development and commercialization of novel central nervous system (CNS) therapies, announces that the innovative AZSTARYS™ (serdexmethylphenidate [SDX] and dexmethylphenidate [d-MPH]), is now available in the U.S. for the treatment of attention deficit hyperactivity disorder (ADHD) symptoms in patients aged 6 years and older.
Boston, MA, March 3, 2021 (PR NEWSWIRE) - Corium, Inc., a commercial-stage biopharmaceutical company leading the development and commercialization of novel central nervous system (CNS) therapies, announced today the U.S. Food and Drug Administration (FDA) approval of once-daily oral capsule AZSTARYS™ (serdexmethylphenidate [SDX] and dexmethylphenidate [d-MPH])…
MENLO PARK, Calif., January 27, 2020 (GLOBE NEWSWIRE) - Corium, Inc., a commercial-stage biopharmaceutical company leading the development of novel transdermal healthcare products that are intended to provide alternative treatment options for patients and their families, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the company's New Drug Application (NDA) for ADLARITY (donepezil transdermal system), its lead investigational agent for the treatment of dementia of the Alzheimer's type in patients with mild, moderate, and severe Alzheimer's disease. FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of July 30th, 2020.
Corium Appoints Perry Sternberg as Chief Executive Officer
MENLO PARK, Calif., April 2, 2019 (GLOBE NEWSWIRE) - Corium, Inc. announced today that its Board of Directors has named Perry Sternberg as Chief Executive Officer. Mr. Sternberg is a senior pharmaceutical executive with commercial experience across a wide range of therapeutic areas in diverse markets…
Gurnet Point Capital Announces Completion of Tender Offer
CAMBRIDGE, Mass., November 27, 2018 - Gurnet Point Capital (“Gurnet Point”), a private investment firm focused on the healthcare and life sciences sectors, announced today that it has completed the previously announced tender offer for all outstanding shares of common stock of Corium International, Inc. (Nasdaq: CORI) (“Corium”), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products….
Corium Announces Agreement for Gurnet Point Capital to Purchase All Outstanding Shares
Total Transaction Valued in Excess of $500 Million , Representing a 50% Premium Gurnet Point Capital to Expand Operations While Focusing on the Approval and Commercialization of Corium's Corplex Donepezil MENLO PARK, Calif. , Oct. 11, 2018 (GLOBE NEWSWIRE) — Corium International, Inc….